CurrentRheuma
Get Weekly

Topic · page 2 of 8

Gout & crystal arthritis

Gout and hyperuricemia, urate-lowering treatment and treat-to-target urate, flare treatment and prophylaxis, comorbidity in gout, calcium pyrophosphate deposition disease and other crystal arthritis

Briefs 41–80 of 301 placed here, newest publication first

Briefs in Gout & crystal arthritis

Newest publication first

  1. Arthritis Care Res (Hoboken)

    Effect of Implementing a Dashboard With or Without a Best Practice Alert on HLA ‐B*58:01 Testing Rates Among Allopurinol Users at VA Medical Centers

    Research article

  2. Arthritis Res Ther

    Effects of adding urinary alkalizer citrate mixture to febuxostat in gout patients with combined-type hyperuricemia and low urine pH: a prospective cohort study

    Cohort study

  3. Arthritis Care Res (Hoboken)

    Characterizing Metabolic Signatures of Air Pollution and Their Association With the Risk of Gout: A Population‐Based Cohort Study

    Cohort study

  4. Lancet Rheumatol

    Worldwide trends in hyperuricaemia from 2000 to 2023: a systematic review and modelling analysis

    Meta-analysis

  5. Arthritis Rheumatol

    Relation of Colchicine to Total Joint Arthroplasty Among People With Gout in a Population‐Based Cohort Study

    Cohort study

  6. J Rheumatol

    High Rates of Degenerative Changes in the Lower Spine in Calcium Pyrophosphate Deposition Disease Compared to Degenerative Disc Disease

    Cohort study

  7. RMD Open

    Proteomic footprint of serum urate concentration and urate transporter ABCG2 dysfunctional polymorphism: a cross-sectional study

    Cross-sectional study

  8. Arthritis Rheumatol

    Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time‐Series Analyses

    Cohort study

  9. Clin Exp Rheumatol

    Triglyceride-Glucose Index for predicting gout flare risk post-urate-lowering therapy: a prospective cohort study

    Cohort study

  10. Arthritis Care Res (Hoboken)

    Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout

    Cohort study

  11. Arthritis Res Ther

    Accelerometer-derived physical activity patterns and risk of incident gout: a prospective cohort study of 97,387 UK Biobank participants

    Cohort study

  12. Rheumatology (Oxford)

    Genetic susceptibility, walking activity and the risk of incident gout

    Cohort study

  13. Arthritis Care Res (Hoboken)

    Serum Uric Acid Levels in Older Adults: Associations With Clinical Outcomes and Implications for Reference Intervals in Those Aged 70 Years and Over

    Cohort study

  14. Rheumatology (Oxford)

    Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy

    Case-control study

  15. J Rheumatol

    Effectivity and Safety of Febuxostat in Reducing Serum Urate in Gout Patients With Chronic Kidney Disease: A Prospective Multicenter ULTRA Registry Study

    Cohort study

  16. Arthritis Care Res (Hoboken)

    Long‐Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration

    Cohort study

  17. Arthritis Care Res (Hoboken)

    Perceptions About Asymptomatic Hyperuricemia and Views About Urate‐Lowering Therapy in People With Asymptomatic Hyperuricemia

    Cross-sectional study

  18. Arthritis Care Res (Hoboken)

    Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial

    Randomized controlled trial

  19. Ann Rheum Dis

    Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study

    Cohort study

  20. Clin Exp Rheumatol

    Prospective 12-month ultrasound evaluation of carotid atherosclerosis, urate deposits, and musculoskeletal inflammation in newly diagnosed gout

    Cohort study

  21. Arthritis Care Res (Hoboken)

    Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

    Secondary analysis

  22. Semin Arthritis Rheum

    The osteoarticular features of Gitelman Syndrome: Chondrocalcinosis and more

    Cohort study

  23. Ann Rheum Dis

    Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial

    Secondary analysis

  24. Rheumatology (Oxford)

    Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies

    Meta-analysis

  25. Rheumatology (Oxford)

    Two-decade trajectories of gout: a multicentre cohort study of 10 658 Chinese patients with gout

    Cross-sectional study

  26. Ann Rheum Dis

    Deconstruction of tophi and synovium defines SPP1+ macrophages involved in extracellular matrix remodelling in gout

    Mechanistic study

  27. J Rheumatol

    Do Monosodium Urate Crystals Reduce at Different Rates in Joints and Tendons During Urate-Lowering Therapy? A Dual-Energy Computed Tomography Study

    Mechanistic study

  28. Rheumatology (Oxford)

    Ten-year cardiovascular risk changes and major adverse events in gout patients

    Cohort study

  29. Arthritis Rheumatol

    Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double‐Blind, Phase 3 Trial in China

    Randomized controlled trial

  30. Lancet Rheumatol

    Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data

    Cohort study

  31. Arthritis Care Res (Hoboken)

    Time Trends and Predictors of Gout Remission Over 6 Years

    Secondary analysis

  32. Scand J Rheumatol

    Similar gout flare incidence rates when using once- or twice-daily 0.5 mg colchicine prophylaxis after the start of xanthine oxidase inhibitors

    Cohort study

  33. Semin Arthritis Rheum

    Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study)

    Cohort study

  34. Semin Arthritis Rheum

    Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trial

    Secondary analysis

  35. Semin Arthritis Rheum

    Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: A modeling analysis of literature aggregate data

    Meta-analysis

  36. Arthritis Rheumatol

    Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations

    Research article

  37. Semin Arthritis Rheum

    Cost-effectiveness of nurse-led home monitoring of serum urate for gout patients starting with urate-lowering therapy in secondary care: a modeling study

    Research article

  38. Scand J Rheumatol

    Genetically predicted serum urate and cancer risk: a Mendelian randomization study

    Research article

  39. Rheumatology (Oxford)

    Mapping MSU crystal deposition within MTP joints in tophaceous gout: a dual-energy CT study

    Cross-sectional study

  40. Ann Rheum Dis

    The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) definition of clinical remission in gout

    Guideline or statement

All 301 Briefs in ExploreShowing Briefs 41–80 of 301, newest first